Egetis Therapeutics Email Format
Pharmaceutical ManufacturingStockholm, Sweden51-200 Employees
Egetis Therapeutics is a Stockholm-based pharmaceutical company in Stockholm County, Sweden, focused on late-stage development to commercialize therapies for serious diseases with significant unmet medical needs in the orphan-drug sector. The company is advancing treatments such as Emcitate (tiratricol) for MCT8 deficiency and has developed educational resources for audiences across North America to increase awareness of the condition. With activities spanning Europe and North America, Egetis aims to translate its late-stage programs into potential treatments for patients with rare diseases. In 2026, the company appointed Tiago Nunes as Chief Medical Officer, effective May 1, as part of ongoing leadership development around its pipeline.